Granules India Ltd.
Research Granules India Ltd. (GRANULES.NS) on Bullrun: market cap INR 225.14B, P/E 30.7, dividend yield 0.2%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerGRANULES.NS
- ExchangeNSE
- CountryIndia
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyINR
- Market capINR 225.14B
- P/E30.7
- Dividend yield0.2%
- Financial periodQ2 2026
- RevenueINR 14.65B
- Net incomeINR 1.80B
- Gross margin65.3%
Valuation Snapshot
latest market cap is INR 225.14B; P/E is 30.7; dividend yield is 0.2%.
Peer valuation comparison
Latest P/E is 30.66x versus a Healthcare sector median of 21.74x (41.0% above).
Latest dividend yield is 0.21% versus a Healthcare sector median of 2.4% (91.3% below).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | INR 225.14B | 30.7 | 0.2% | 1.75 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 1.75 INR, yield 0.2%.
About Granules India Ltd.
Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), finished dosages (FDs), and peptides CDMO in India and internationally. It offers paracetamol, metformin, guaifenesin, ibuprofen, and methocarbamol, as well as prescription and over-the-counter products. The company also develops and manufactures tablets, capsules, press fits, oral solutions, suspensions, and powder for oral solutions.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Granules India Ltd.'s market cap?
Granules India Ltd.'s market capitalization is INR 225.14B.
What is Granules India Ltd.'s P/E ratio?
Granules India Ltd.'s price-to-earnings (P/E) ratio is 30.7.
Does Granules India Ltd. pay a dividend?
Granules India Ltd. has a dividend yield of 0.2%.
What does Granules India Ltd. do?
Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), finished dosages (FDs), and peptides CDMO in India and internationally. It offers paracetamol, metformin, guaifenesin, ibuprofen, and methocarbamol, as well as prescription and over-the-counter products. The company also develops and manufactures tablets, capsules, press fits, oral solutions, suspensions, and powder for oral solutions. In addition, it provides development and manufacturing solutions for peptides, peptide fragments, and amino acid derivatives.